Market Research Logo

Cardiovascular Disorders Drug Development Pipeline Review, 2017

Cardiovascular Disorders Drug Development Pipeline Review, 2017

Summary


Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

There are over 1,200 pipeline products within the CVD therapy area. Over 50% of these products are small molecules however there is also diversification with regards to molecule types within the pipeline. In addition, the molecular targets in the pipeline are considerably diverse with a high frequency of products acting on targets related to lipid metabolism and those which act on elements of the coagulation cascade.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as PCSK9 inhibitors and direct factor Xa inhibitors.

The report provides comprehensive information on the pipeline development landscape for Hypertension, Dyslipidemia, Venous thromboembolism and Heart failure, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

  • Which companies are the most active within the pipeline for CVD?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • Executive Summary
  • Introduction
    • Cardiovascular Disorders Report Coverage
    • Hypertension Overview
    • Dyslipidemia Overview
    • Thromboembolism Overview
    • Heart Failure Overview
      • Acute Heart Failure
      • Congestive Heart Failure (Heart Failure)
      • Chronic Heart Failure
  • Therapeutics Development
    • Hypertension
      • Pipeline Products for Hypertension - Overview
        • Table Figure 1: Number of Products under Development for Hypertension
        • Table Number of Products under Development for Hypertension
      • Pipeline Products for Hypertension - Comparative Analysis
        • Table Figure 2: Number of Products under Development for Hypertension - Comparative Analysis
        • Table Number of Products under Development for Hypertension - Comparative Analysis
    • Dyslipidemia
      • Pipeline Products for Dyslipidemia - Overview
        • Table Figure 3: Number of Products under Development for Dyslipidemia
        • Table Number of Products under Development for Dyslipidemia
      • Pipeline Products for Dyslipidemia - Comparative Analysis
        • Table Figure 4: Number of Products under Development for Dyslipidemia - Comparative Analysis
        • Table Number of Products under Development for Dyslipidemia - Comparative Analysis
    • Thromboembolism
      • Pipeline Products for Thromboembolism - Overview
        • Table Figure 5: Number of Products under Development for Thromboembolism
        • Table Number of Products under Development for Thromboembolism
      • Pipeline Products for Thromboembolism - Comparative Analysis
        • Table Figure 6: Number of Products under Development for Thromboembolism - Comparative Analysis
        • Table Number of Products under Development for Thromboembolism - Comparative Analysis
    • Heart Failure
      • Acute Heart Failure
        • Table Figure 7: Number of Products under Development for Acute Heart Failure
        • Table Number of Products under Development for Acute Heart Failure
      • Congestive Heart Failure (Heart Failure)
        • Table Figure 8: Number of Products under Development for Congestive Heart Failure (Heart Failure)
        • Table Number of Products under Development for Congestive Heart Failure (Heart Failure)
      • Pipeline Products for Congestive Heart Failure (Heart Failure) - Comparative Analysis
        • Table Figure 9: Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis
        • Table Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis
      • Chronic Heart Failure
        • Table Figure 10: Number of Products under Development for Chronic Heart Failure
        • Table Number of Products under Development for Chronic Heart Failure
      • Pipeline Products for Chronic Heart Failure - Comparative Analysis
        • Table Figure 11: Number of Products under Development for Chronic Heart Failure - Comparative Analysis
        • Table Number of Products under Development for Chronic Heart Failure - Comparative Analysis
  • Therapeutics under Development by Companies
    • Hypertension
      • Table Figure 12: Number of Products under Development by Companies, Hypertension
      • Table Number of Products under Development by Companies, Hypertension
    • Dyslipidemia
      • Table Figure 13: Number of Products under Development by Companies, Dyslipidemia
      • Table Number of Products under Development by Companies, Dyslipidemia
    • Thromboembolism
      • Table Figure 14: Number of Products under Development by Companies, Thromboembolism
      • Table Number of Products under Development by Companies, Thromboembolism
    • Heart Failure
      • Acute Heart Failure
        • Table Figure 15: Number of Products under Development by Companies, Acute Heart Failure
        • Table Number of Products under Development by Companies, Acute Heart Failure
      • Congestive Heart Failure (Heart Failure)
        • Table Figure 16: Number of Products under Development by Companies, Congestive Heart Failure (Heart Failure)
        • Table Number of Products under Development by Companies, Congestive Heart Failure (Heart Failure)
      • Chronic Heart Failure
        • Table Figure 17: Number of Products under Development by Companies, Chronic Heart Failure
        • Table Number of Products under Development by Companies, Chronic Heart Failure
  • Therapeutics under Investigation by Universities/Institutes
    • Hypertension
      • Table Figure 18: Number of Products under Investigation by Universities/Institutes, Hypertension
      • Table Number of Products under Investigation by Universities/Institutes, Hypertension
    • Dyslipidemia
      • Table Figure 19: Number of Products under Investigation by Universities/Institutes, Dyslipidemia
      • Table Number of Products under Investigation by Universities/Institutes, Dyslipidemia
    • Thromboembolism
      • Table Number of Products under Investigation by Universities/Institutes, Thromboembolism
    • Heart Failure
      • Congestive Heart Failure (Heart Failure)
        • Table Figure 20: Number of Products under Investigation by Universities/Institutes, Congestive Heart Failure (Heart Failure)
        • Table Number of Products under Investigation by Universities/Institutes, Congestive Heart Failure (Heart Failure)
      • Chronic Heart Failure
        • Table Number of Products under Investigation by Universities/Institutes, Chronic Heart Failure
  • Pipeline Products Glance
    • Hypertension
      • Late Stage Products
        • Table Figure 21: Comparative Analysis by Late Stage Development, Hypertension
        • Table Comparative Analysis by Late Stage Development, Hypertension
      • Clinical Stage Products
        • Table Figure 22: Comparative Analysis by Clinical Stage Development, Hypertension
        • Table Comparative Analysis by Clinical Stage Development, Hypertension
      • Early Stage Products
        • Table Figure 23: Comparative Analysis by Early Stage Products, Hypertension
        • Table Comparative Analysis by Early Stage Development, Hypertension
    • Dyslipidemia
      • Late Stage Products
        • Table Figure 24: Comparative Analysis by Late Stage Development, Dyslipidemia
        • Table Comparative Analysis by Late Stage Development, Dyslipidemia
      • Clinical Stage Products
        • Table Figure 25: Comparative Analysis by Clinical Stage Development, Dyslipidemia
        • Table Comparative Analysis by Clinical Stage Development, Dyslipidemia
      • Early Stage Products
        • Table Figure 26: Comparative Analysis by Early Stage Products, Dyslipidemia
        • Table Comparative Analysis by Early Stage Development, Dyslipidemia
      • Unknown Stage Products
        • Table Comparative Analysis by Unknown Stage Development, Dyslipidemia
    • Thromboembolism
      • Late Stage Products
        • Table Figure 27: Comparative Analysis by Late Stage Development, Thromboembolism
        • Table Comparative Analysis by Late Stage Development, Thromboembolism
      • Clinical Stage Products
        • Table Figure 28: Comparative Analysis by Clinical Stage Development, Thromboembolism
        • Table Comparative Analysis by Clinical Stage Development, Thromboembolism
      • Early Stage Products
        • Table Figure 29: Comparative Analysis by Early Stage Products, Thromboembolism
        • Table Comparative Analysis by Early Stage Development, Thromboembolism
    • Heart Failure
      • Acute Heart Failure
        • Table Comparative Analysis by Late Stage Development, Acute Heart Failure
      • Clinical Stage Products
        • Table Figure 30: Comparative Analysis by Clinical Stage Development, Acute Heart Failure
        • Table Comparative Analysis by Clinical Stage Development, Acute Heart Failure
      • Early Stage Products
        • Table Comparative Analysis by Early Stage Development, Acute Heart Failure
      • Congestive Heart Failure (Heart Failure)
        • Table Figure 31: Comparative Analysis by Late Stage Development, Congestive Heart Failure (Heart Failure)
        • Table Comparative Analysis by Late Stage Development, Congestive Heart Failure (Heart Failure)
      • Clinical Stage Products
        • Table Figure 32: Comparative Analysis by Clinical Stage Development, Congestive Heart Failure (Heart Failure)
        • Table Comparative Analysis by Clinical Stage Development, Congestive Heart Failure (Heart Failure)
      • Early Stage Products
        • Table Figure 33: Comparative Analysis by Early Stage Products, Congestive Heart Failure (Heart Failure)
        • Table Comparative Analysis by Early Stage Development, Congestive Heart Failure (Heart Failure)
      • Unknown Stage Products
        • Table Comparative Analysis by Unknown Stage Development, Congestive Heart Failure (Heart Failure)
      • Chronic Heart Failure
        • Table Comparative Analysis by Late Stage Development, Chronic Heart Failure
      • Clinical Stage Products
        • Table Figure 34: Comparative Analysis by Clinical Stage Development, Chronic Heart Failure
        • Table Comparative Analysis by Clinical Stage Development, Chronic Heart Failure
      • Early Stage Products
        • Table Figure 35: Comparative Analysis by Early Stage Products, Chronic Heart Failure
        • Table Comparative Analysis by Early Stage Development, Chronic Heart Failure
  • Products under Development by Companies
    • Hypertension
      • Table Products under Development by Companies, Hypertension
    • Dyslipidemia
      • Table Products under Development by Companies, Dyslipidemia
    • Thromboembolism
      • Table Products under Development by Companies, Thromboembolism
    • Heart Failure
      • Acute Heart Failure
        • Table Products under Development by Companies, Acute Heart Failure
      • Congestive Heart Failure (Heart Failure)
        • Table Products under Development by Companies, Congestive Heart Failure (Heart Failure)
      • Chronic Heart Failure
        • Table Products under Development by Companies, Chronic Heart Failure
  • Products under Investigation by Universities/Institutes
    • Hypertension
      • Table Products under Investigation by Universities/Institutes, Hypertension
    • Dyslipidemia
      • Table Products under Investigation by Universities/Institutes, Dyslipidemia
    • Thromboembolism
      • Table Products under Investigation by Universities/Institutes, Thromboembolism
    • Heart Failure
      • Congestive Heart Failure (Heart Failure)
        • Table Products under Investigation by Universities/Institutes, Congestive Heart Failure (Heart Failure)
      • Chronic Heart Failure
        • Table Products under Investigation by Universities/Institutes, Chronic Heart Failure
  • Companies Involved in Therapeutics Development
    • Hypertension
      • A1M Pharma AB
        • Table Hypertension - Pipeline by A1M Pharma AB
      • AbbVie Inc
        • Table Hypertension - Pipeline by AbbVie Inc
      • Actelion Ltd
        • Table Hypertension - Pipeline by Actelion Ltd
      • Afferent Pharmaceuticals Inc
        • Table Hypertension - Pipeline by Afferent Pharmaceuticals Inc
      • Alnylam Pharmaceuticals Inc
        • Table Hypertension - Pipeline by Alnylam Pharmaceuticals Inc
      • Anacor Pharmaceuticals Inc
        • Table Hypertension - Pipeline by Anacor Pharmaceuticals Inc
      • AnGes MG Inc
        • Table Hypertension - Pipeline by AnGes MG Inc
      • APT Therapeutics Inc
        • Table Hypertension - Pipeline by APT Therapeutics Inc
      • Arena Pharmaceuticals Inc
        • Table Hypertension - Pipeline by Arena Pharmaceuticals Inc
      • Ascendis Pharma A/S
        • Table Hypertension - Pipeline by Ascendis Pharma A/S
      • Asklepion Pharmaceuticals LLC
        • Table Hypertension - Pipeline by Asklepion Pharmaceuticals LLC
      • AVEO Pharmaceuticals Inc
        • Table Hypertension - Pipeline by AVEO Pharmaceuticals Inc
      • Bayer AG
        • Table Hypertension - Pipeline by Bayer AG
      • Bial - Portela & Ca SA
        • Table Hypertension - Pipeline by Bial - Portela & Ca SA
      • Biolab Farmaceutica Ltda
        • Table Hypertension - Pipeline by Biolab Farmaceutica Ltda
      • BioRestorative Therapies Inc
        • Table Hypertension - Pipeline by BioRestorative Therapies Inc
      • Boryung Pharmaceutical Co Ltd
        • Table Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd
      • Cellceutix Corp
        • Table Hypertension - Pipeline by Cellceutix Corp
      • Celsion Corp
        • Table Hypertension - Pipeline by Celsion Corp
      • Celtaxsys Inc
        • Table Hypertension - Pipeline by Celtaxsys Inc
      • Chong Kun Dang Pharmaceutical Corp
        • Table Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp
      • CJ HealthCare Corp
        • Table Hypertension - Pipeline by CJ HealthCare Corp
      • Complexa Inc
        • Table Hypertension - Pipeline by Complexa Inc
      • Conatus Pharmaceuticals Inc
        • Table Hypertension - Pipeline by Conatus Pharmaceuticals Inc
      • Corion Biotech Srl
        • Table Hypertension - Pipeline by Corion Biotech Srl
      • Cumberland Pharmaceuticals Inc
        • Table Hypertension - Pipeline by Cumberland Pharmaceuticals Inc
      • Cytokinetics Inc
        • Table Hypertension - Pipeline by Cytokinetics Inc
      • Daewoong Pharmaceutical Co Ltd
        • Table Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd
      • Daiichi Sankyo Company Ltd
        • Table Hypertension - Pipeline by Daiichi Sankyo Company Ltd
      • DiaMedica Inc
        • Table Hypertension - Pipeline by DiaMedica Inc
      • Eli Lilly and Company
        • Table Hypertension - Pipeline by Eli Lilly and Company
      • Esperion Therapeutics Inc
        • Table Hypertension - Pipeline by Esperion Therapeutics Inc
      • F. Hoffmann-La Roche Ltd
        • Table Hypertension - Pipeline by F. Hoffmann-La Roche Ltd
      • Ferring International Center SA
        • Table Hypertension - Pipeline by Ferring International Center SA
      • Galectin Therapeutics Inc
        • Table Hypertension - Pipeline by Galectin Therapeutics Inc
      • Genextra Spa
        • Table Hypertension - Pipeline by Genextra Spa
      • Gilead Sciences Inc
        • Table Hypertension - Pipeline by Gilead Sciences Inc
      • GlaxoSmithKline Plc
        • Table Hypertension - Pipeline by GlaxoSmithKline Plc
      • Glenveigh Medical LLC
        • Table Hypertension - Pipeline by Glenveigh Medical LLC
      • HanAll Biopharma Co Ltd
        • Table Hypertension - Pipeline by HanAll Biopharma Co Ltd
      • Hanmi Pharmaceuticals Co Ltd
        • Table Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd
      • HitGen LTD
        • Table Hypertension - Pipeline by HitGen LTD
      • Innopharmax Inc
        • Table Hypertension - Pipeline by Innopharmax Inc
      • Insmed Inc
        • Table Hypertension - Pipeline by Insmed Inc
      • INVENT Pharmaceuticals Inc
        • Table Hypertension - Pipeline by INVENT Pharmaceuticals Inc
      • Ionis Pharmaceuticals Inc
        • Table Hypertension - Pipeline by Ionis Pharmaceuticals Inc
      • Ironwood Pharmaceuticals Inc
        • Table Hypertension - Pipeline by Ironwood Pharmaceuticals Inc
      • Jeil Pharmaceutical Co Ltd
        • Table Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd
      • Johnson & Johnson
        • Table Hypertension - Pipeline by Johnson & Johnson
      • JW Pharmaceutical Corp
        • Table Hypertension - Pipeline by JW Pharmaceutical Corp
      • Kowa Company Ltd
        • Table Hypertension - Pipeline by Kowa Company Ltd
      • Leading BioSciences Inc
        • Table Hypertension - Pipeline by Leading BioSciences Inc
      • Lee's Pharmaceutical Holdings Ltd
        • Table Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd
      • Les Laboratoires Servier SAS
        • Table Hypertension - Pipeline by Les Laboratoires Servier SAS
      • LFB SA
        • Table Hypertension - Pipeline by LFB SA
      • LG Life Science LTD
        • Table Hypertension - Pipeline by LG Life Science LTD
      • LinXis BV
        • Table Hypertension - Pipeline by LinXis BV
      • Liquidia Technologies Inc
        • Table Hypertension - Pipeline by Liquidia Technologies Inc
      • Lotus Pharmaceutical Co Ltd
        • Table Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd
      • MannKind Corp
        • Table Hypertension - Pipeline by MannKind Corp
      • Mast Therapeutics Inc
        • Table Hypertension - Pipeline by Mast Therapeutics Inc
      • Merck & Co Inc
        • Table Hypertension - Pipeline by Merck & Co Inc
      • Mezzion Pharma Co Ltd
        • Table Hypertension - Pipeline by Mezzion Pharma Co Ltd
      • miRagen Therapeutics Inc
        • Table Hypertension - Pipeline by miRagen Therapeutics Inc
      • Mitsubishi Tanabe Pharma Corp
        • Table Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp
      • Morphogen-IX Ltd
        • Table Hypertension - Pipeline by Morphogen-IX Ltd
      • Neurim Pharmaceuticals Ltd
        • Table Hypertension - Pipeline by Neurim Pharmaceuticals Ltd
      • Nippon Kayaku Co Ltd
        • Table Hypertension - Pipeline by Nippon Kayaku Co Ltd
      • Nippon Shinyaku Co Ltd
        • Table Hypertension - Pipeline by Nippon Shinyaku Co Ltd
      • Novartis AG
        • Table Hypertension - Pipeline by Novartis AG
      • Noxamet Ltd
        • Table Hypertension - Pipeline by Noxamet Ltd
      • Omeros Corp
        • Table Hypertension - Pipeline by Omeros Corp
      • Peloton Therapeutics Inc
        • Table Hypertension - Pipeline by Peloton Therapeutics Inc
      • Pfizer Inc
        • Table Hypertension - Pipeline by Pfizer Inc
      • PhaseBio Pharmaceuticals Inc
        • Table Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc
      • Pluristem Therapeutics Inc
        • Table Hypertension - Pipeline by Pluristem Therapeutics Inc
      • Polyphor Ltd
        • Table Hypertension - Pipeline by Polyphor Ltd
      • Proteo Inc
        • Table Hypertension - Pipeline by Proteo Inc
      • Pulmokine Inc
        • Table Hypertension - Pipeline by Pulmokine Inc
      • Quantum Genomics SA
        • Table Hypertension - Pipeline by Quantum Genomics SA
      • Reata Pharmaceuticals Inc
        • Table Hypertension - Pipeline by Reata Pharmaceuticals Inc
      • RedHill Biopharma Ltd
        • Table Hypertension - Pipeline by RedHill Biopharma Ltd
      • Respira Therapeutics Inc
        • Table Hypertension - Pipeline by Respira Therapeutics Inc
      • Reviva Pharmaceuticals Inc
        • Table Hypertension - Pipeline by Reviva Pharmaceuticals Inc
      • Sanofi
        • Table Hypertension - Pipeline by Sanofi
      • Selten Pharma Inc
        • Table Hypertension - Pipeline by Selten Pharma Inc
      • Serodus ASA
        • Table Hypertension - Pipeline by Serodus ASA
      • Shanghai Pharmaceutical Co Ltd
        • Table Hypertension - Pipeline by Shanghai Pharmaceutical Co Ltd
      • Silence Therapeutics Plc
        • Table Hypertension - Pipeline by Silence Therapeutics Plc
      • Simcere Pharmaceutical Group
        • Table Hypertension - Pipeline by Simcere Pharmaceutical Group
      • SteadyMed Therapeutics Inc
        • Table Hypertension - Pipeline by SteadyMed Therapeutics Inc
      • Suda Ltd
        • Table Hypertension - Pipeline by Suda Ltd
      • Sumitomo Dainippon Pharma Co Ltd
        • Table Hypertension - Pipeline by Sumitomo Dainippon Pharma Co Ltd
      • Takeda Pharmaceutical Company Ltd
        • Table Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd
      • The Medicines Company
        • Table Hypertension - Pipeline by The Medicines Company
      • Theravance Biopharma Inc
        • Table Hypertension - Pipeline by Theravance Biopharma Inc
      • Toray Industries Inc
        • Table Hypertension - Pipeline by Toray Industries Inc
      • Torrent Pharmaceuticals Ltd
        • Table Hypertension - Pipeline by Torrent Pharmaceuticals Ltd
      • TSH Biopharm Corporation Ltd
        • Table Hypertension - Pipeline by TSH Biopharm Corporation Ltd
      • United Therapeutics Corp
        • Table Hypertension - Pipeline by United Therapeutics Corp
      • VBS Pharmaceuticals
        • Table Hypertension - Pipeline by VBS Pharmaceuticals
      • Vectura Group Plc
        • Table Hypertension - Pipeline by Vectura Group Plc
      • VG Life Sciences Inc
        • Table Hypertension - Pipeline by VG Life Sciences Inc
      • Vicore Pharma AB
        • Table Hypertension - Pipeline by Vicore Pharma AB
      • XORTX Pharma Corp
        • Table Hypertension - Pipeline by XORTX Pharma Corp
      • XuanZhu Pharma Co Ltd
        • Table Hypertension - Pipeline by XuanZhu Pharma Co Ltd
      • Yuhan Corp
        • Table Hypertension - Pipeline by Yuhan Corp
    • Dyslipidemia
      • Acasti Pharma Inc.
        • Table Dyslipidemia - Pipeline by Acasti Pharma Inc.
      • AFFiRiS AG
        • Table Dyslipidemia - Pipeline by AFFiRiS AG
      • Akcea Therapeutics Inc
        • Table Dyslipidemia - Pipeline by Akcea Therapeutics Inc
      • Allergan Plc
        • Table Dyslipidemia - Pipeline by Allergan Plc
      • Alnylam Pharmaceuticals, Inc.
        • Table Dyslipidemia - Pipeline by Alnylam Pharmaceuticals, Inc.
      • Amgen Inc.
        • Table Dyslipidemia - Pipeline by Amgen Inc.
      • Arisaph Pharmaceuticals, Inc.
        • Table Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc.
      • AstraZeneca Plc
        • Table Dyslipidemia - Pipeline by AstraZeneca Plc
      • BASF SE
        • Table Dyslipidemia - Pipeline by BASF SE
      • BCWorld Pharm Co. Ltd.
        • Table Dyslipidemia - Pipeline by BCWorld Pharm Co. Ltd.
      • BioRestorative Therapies, Inc.
        • Table Dyslipidemia - Pipeline by BioRestorative Therapies, Inc.
      • Cadila Pharmaceuticals Limited
        • Table Dyslipidemia - Pipeline by Cadila Pharmaceuticals Limited
      • Cardax, Inc.
        • Table Dyslipidemia - Pipeline by Cardax, Inc.
      • Catabasis Pharmaceuticals, Inc.
        • Table Dyslipidemia - Pipeline by Catabasis Pharmaceuticals, Inc.
      • Cerenis Therapeutics Holding SA
        • Table Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA
      • Chong Kun Dang Pharmaceutical Corp.
        • Table Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp.
      • CJ HealthCare Corp.
        • Table Dyslipidemia - Pipeline by CJ HealthCare Corp.
      • Connexios Life Sciences Pvt. Ltd.
        • Table Dyslipidemia - Pipeline by Connexios Life Sciences Pvt. Ltd.
      • CymaBay Therapeutics, Inc.
        • Table Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc.
      • Daewoong Pharmaceutical Co., Ltd.
        • Table Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd.
      • Daiichi Sankyo Company, Limited
        • Table Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited
      • Debiopharm International SA
        • Table Dyslipidemia - Pipeline by Debiopharm International SA
      • Eli Lilly and Company
        • Table Dyslipidemia - Pipeline by Eli Lilly and Company
      • Esperion Therapeutics, Inc.
        • Table Dyslipidemia - Pipeline by Esperion Therapeutics, Inc.
      • Gemphire Therapeutics Inc.
        • Table Dyslipidemia - Pipeline by Gemphire Therapeutics Inc.
      • GlaxoSmithKline Plc
        • Table Dyslipidemia - Pipeline by GlaxoSmithKline Plc
      • Golden Biotechnology Corp.
        • Table Dyslipidemia - Pipeline by Golden Biotechnology Corp.
      • HanAll Biopharma Co., Ltd.
        • Table Dyslipidemia - Pipeline by HanAll Biopharma Co., Ltd.
      • Hanmi Pharmaceuticals, Co. Ltd.
        • Table Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd.
      • Huons Co., Ltd.
        • Table Dyslipidemia - Pipeline by Huons Co., Ltd.
      • Hyundai Pharmaceutical Co., Ltd.
        • Table Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd.
      • Innovent Biologics, Inc.
        • Table Dyslipidemia - Pipeline by Innovent Biologics, Inc.
      • IPCA Laboratories Limited
        • Table Dyslipidemia - Pipeline by IPCA Laboratories Limited
      • Jeil Pharmaceutical Co., Ltd.
        • Table Dyslipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd.
      • Jenrin Discovery, Inc.
        • Table Dyslipidemia - Pipeline by Jenrin Discovery, Inc.
      • JW Pharmaceutical Corporation
        • Table Dyslipidemia - Pipeline by JW Pharmaceutical Corporation
      • Kissei Pharmaceutical Co., Ltd.
        • Table Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd.
      • Kotobuki Pharmaceutical Co., Ltd.
        • Table Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd.
      • Kowa Company, Ltd.
        • Table Dyslipidemia - Pipeline by Kowa Company, Ltd.
      • Kymab Limited
        • Table Dyslipidemia - Pipeline by Kymab Limited
      • Kyorin Pharmaceutical Co., Ltd.
        • Table Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co., Ltd.
      • LG Life Science LTD.
        • Table Dyslipidemia - Pipeline by LG Life Science LTD.
      • Lipicard Technologies Limited
        • Table Dyslipidemia - Pipeline by Lipicard Technologies Limited
      • Lipigon Pharmaceuticals AB
        • Table Dyslipidemia - Pipeline by Lipigon Pharmaceuticals AB
      • LipimetiX Development Inc
        • Table Dyslipidemia - Pipeline by LipimetiX Development Inc
      • Lotus Pharmaceutical Co., Ltd.
        • Table Dyslipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd.
      • Matinas BioPharma Holdings, Inc.
        • Table Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc.
      • Merck & Co., Inc.
        • Table Dyslipidemia - Pipeline by Merck & Co., Inc.
      • Nimbus Therapeutics, LLC
        • Table Dyslipidemia - Pipeline by Nimbus Therapeutics, LLC
      • Nippon Chemiphar Co., Ltd.
        • Table Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd.
      • Omeros Corporation
        • Table Dyslipidemia - Pipeline by Omeros Corporation
      • Pfizer Inc.
        • Table Dyslipidemia - Pipeline by Pfizer Inc.
      • Pharmena SA
        • Table Dyslipidemia - Pipeline by Pharmena SA
      • Protalix BioTherapeutics, Inc.
        • Table Dyslipidemia - Pipeline by Protalix BioTherapeutics, Inc.
      • Regeneron Pharmaceuticals Inc
        • Table Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc
      • Sancilio & Company, Inc.
        • Table Dyslipidemia - Pipeline by Sancilio & Company, Inc.
      • Takeda Pharmaceutical Company Limited
        • Table Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited
      • Thetis Pharmaceuticals LLC
        • Table Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC
      • Torrent Pharmaceuticals Limited
        • Table Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited
      • Yuhan Corporation
        • Table Dyslipidemia - Pipeline by Yuhan Corporation
      • Zydus Cadila Healthcare Limited
        • Table Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited
    • Thromboembolism
      • Bayer AG
        • Table Thromboembolism - Pipeline by Bayer AG
      • Cereno Scientific AB
        • Table Thromboembolism - Pipeline by Cereno Scientific AB
      • China Biologic Products, Inc.
        • Table Thromboembolism - Pipeline by China Biologic Products, Inc.
      • Daiichi Sankyo Company, Limited
        • Table Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited
      • F. Hoffmann-La Roche Ltd.
        • Table Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd.
      • Gamma Therapeutics, Inc.
        • Table Thromboembolism - Pipeline by Gamma Therapeutics, Inc.
      • GlycoMimetics, Inc.
        • Table Thromboembolism - Pipeline by GlycoMimetics, Inc.
      • Green Cross Corporation
        • Table Thromboembolism - Pipeline by Green Cross Corporation
      • Ionis Pharmaceuticals, Inc.
        • Table Thromboembolism - Pipeline by Ionis Pharmaceuticals, Inc.
      • Portola Pharmaceuticals, Inc.
        • Table Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc.
      • The International Biotechnology Center (IBC) Generium
        • Table Thromboembolism - Pipeline by The International Biotechnology Center (IBC) Generium
    • Heart Failure
      • Acute Heart Failure
        • Table Acute Heart Failure - Pipeline by Amgen Inc.
      • Capricor Therapeutics, Inc.
        • Table Acute Heart Failure - Pipeline by Capricor Therapeutics, Inc.
      • Eli Lilly and Company
        • Table Acute Heart Failure - Pipeline by Eli Lilly and Company
      • Lee's Pharmaceutical Holdings Limited
        • Table Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited
      • Novartis AG
        • Table Acute Heart Failure - Pipeline by Novartis AG
      • Ono Pharmaceutical Co., Ltd.
        • Table Acute Heart Failure - Pipeline by Ono Pharmaceutical Co., Ltd.
      • PhaseBio Pharmaceuticals, Inc.
        • Table Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc.
      • Trevena, Inc.
        • Table Acute Heart Failure - Pipeline by Trevena, Inc.
      • Congestive Heart Failure (Heart Failure)
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc.
      • AnGes MG, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG, Inc.
      • Araim Pharmaceuticals, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Araim Pharmaceuticals, Inc.
      • ARCA biopharma, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by ARCA biopharma, Inc.
      • Ascelegen Therapeutics, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Ascelegen Therapeutics, Inc.
      • Asterias Biotherapeutics, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Asterias Biotherapeutics, Inc.
      • Athersys, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Athersys, Inc.
      • Bayer AG
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG
      • BEAT BioTherapeutics Corp.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp.
      • BioCardia, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia, Inc.
      • Bristol-Myers Squibb Company
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company
      • Capricor Therapeutics, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics, Inc.
      • Cell Therapy Limited
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Cell Therapy Limited
      • Celyad SA
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Celyad SA
      • Eli Lilly and Company
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Eli Lilly and Company
      • FibroGen, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen, Inc.
      • GlaxoSmithKline Plc
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline Plc
      • Glucox Biotech AB
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Glucox Biotech AB
      • Heart Metabolics Limited
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Heart Metabolics Limited
      • Hemostemix Ltd
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Ltd
      • Innopharmax Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc.
      • Jiangsu Hengrui Medicine Co., Ltd.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd.
      • Juventas Therapeutics, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics, Inc.
      • La Jolla Pharmaceutical Company
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company
      • Laboratoires Pierre Fabre SA
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Laboratoires Pierre Fabre SA
      • Lead Discovery Center GmbH
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Lead Discovery Center GmbH
      • Lee's Pharmaceutical Holdings Limited
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Limited
      • Les Laboratoires Servier SAS
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS
      • Lonestar Heart, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart, Inc.
      • Mast Therapeutics, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Mast Therapeutics, Inc.
      • Merck & Co., Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co., Inc.
      • Mesoblast Limited
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Limited
      • miRagen Therapeutics, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by miRagen Therapeutics, Inc.
      • MorphoSys AG
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by MorphoSys AG
      • NanoCor Therapeutics, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by NanoCor Therapeutics, Inc.
      • Neurocrine Biosciences, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Neurocrine Biosciences, Inc.
      • Novartis AG
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG
      • Nuo Therapeutics, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Nuo Therapeutics, Inc.
      • Ono Pharmaceutical Co., Ltd.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Ono Pharmaceutical Co., Ltd.
      • Palatin Technologies, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies, Inc.
      • Pfizer Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Pfizer Inc.
      • PharmaIN Corporation
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corporation
      • PhaseBio Pharmaceuticals, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals, Inc.
      • Pluristem Therapeutics Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Pluristem Therapeutics Inc.
      • Quantum Genomics SA
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Quantum Genomics SA
      • Recardio GmbH
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH
      • RedHill Biopharma Ltd.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by RedHill Biopharma Ltd.
      • Renova Therapeutics Inc
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Renova Therapeutics Inc
      • scPharmaceuticals Inc
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by scPharmaceuticals Inc
      • Stealth BioTherapeutics Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc.
      • Stemedica Cell Technologies, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies, Inc.
      • Target Heart Biotec Srl
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Target Heart Biotec Srl
      • Theravance Biopharma, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma, Inc.
      • TiGenix NV
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV
      • Torrent Pharmaceuticals Limited
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Limited
      • Trevena, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Trevena, Inc.
      • U.S. Stem Cell, Inc.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell, Inc.
      • Vichem Chemie Research Ltd.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Vichem Chemie Research Ltd.
      • Vicore Pharma AB
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB
      • Zensun (Shanghai) Sci & Tech Co., Ltd.
        • Table Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd.
      • Chronic Heart Failure
        • Table Chronic Heart Failure - Pipeline by Amgen Inc.
      • AnGes MG, Inc.
        • Table Chronic Heart Failure - Pipeline by AnGes MG, Inc.
      • AstraZeneca Plc
        • Table Chronic Heart Failure - Pipeline by AstraZeneca Plc
      • Bayer AG
        • Table Chronic Heart Failure - Pipeline by Bayer AG
      • Capricor Therapeutics, Inc.
        • Table Chronic Heart Failure - Pipeline by Capricor Therapeutics, Inc.
      • Celyad SA
        • Table Chronic Heart Failure - Pipeline by Celyad SA
      • Juventas Therapeutics, Inc.
        • Table Chronic Heart Failure - Pipeline by Juventas Therapeutics, Inc.
      • Laboratoires Pierre Fabre SA
        • Table Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA
      • Les Laboratoires Servier SAS
        • Table Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS
      • Mast Therapeutics, Inc.
        • Table Chronic Heart Failure - Pipeline by Mast Therapeutics, Inc.
      • Mesoblast Limited
        • Table Chronic Heart Failure - Pipeline by Mesoblast Limited
      • Novartis AG
        • Table Chronic Heart Failure - Pipeline by Novartis AG
      • Pfizer Inc.
        • Table Chronic Heart Failure - Pipeline by Pfizer Inc.
      • scPharmaceuticals Inc
        • Table Chronic Heart Failure - Pipeline by scPharmaceuticals Inc
      • Stemedica Cell Technologies, Inc.
        • Table Chronic Heart Failure - Pipeline by Stemedica Cell Technologies, Inc.
      • Theravance Biopharma, Inc.
        • Table Chronic Heart Failure - Pipeline by Theravance Biopharma, Inc.
      • Vichem Chemie Research Ltd.
        • Table Chronic Heart Failure - Pipeline by Vichem Chemie Research Ltd.
      • Zensun (Shanghai) Sci & Tech Co., Ltd.
        • Table Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd.
  • Therapeutics Assessment
    • Hypertension
      • Assessment by Monotherapy Products
        • Table Figure 36: Assessment by Monotherapy Products, Hypertension
        • Table Assessment by Monotherapy Products, Hypertension
      • Assessment by Combination Products
        • Table Figure 37: Assessment by Combination Products, Hypertension
        • Table Assessment by Combination Products, Hypertension
      • Assessment by Target
        • Table Figure 38: Number of Products by Top 10 Targets, Hypertension
        • Table Figure 39: Number of Products by Stage and Top 10 Targets, Hypertension
        • Table Number of Products by Stage and Target, Hypertension
      • Assessment by Mechanism of Action
        • Table Figure 40: Number of Products by Top 10 Mechanism of Actions, Hypertension
        • Table Figure 41: Number of Products by Stage and Top 10 Mechanism of Actions, Hypertension
        • Table Number of Products by Stage and Mechanism of Action, Hypertension
      • Assessment by Route of Administration
        • Table Figure 42: Number of Products by Top 10 Routes of Administration, Hypertension
        • Table Figure 43: Number of Products by Stage and Top 10 Routes of Administration, Hypertension
        • Table Number of Products by Stage and Route of Administration, Hypertension
      • Assessment by Molecule Type
        • Table Figure 44: Number of Products by Top 10 Molecule Types, Hypertension
        • Table Figure 45: Number of Products by Stage and Top 10 Molecule Types, Hypertension
        • Table Number of Products by Stage and Molecule Type, Hypertension
    • Dyslipidemia
      • Assessment by Monotherapy Products
        • Table Figure 46: Assessment by Monotherapy Products, Dyslipidemia
        • Table Assessment by Monotherapy Products, Dyslipidemia
      • Assessment by Combination Products
        • Table Figure 47: Assessment by Combination Products, Dyslipidemia
        • Table Assessment by Combination Products, Dyslipidemia
      • Assessment by Target
        • Table Figure 48: Number of Products by Top 10 Targets, Dyslipidemia
        • Table Figure 49: Number of Products by Stage and Top 10 Targets, Dyslipidemia
        • Table Number of Products by Stage and Target, Dyslipidemia
      • Assessment by Mechanism of Action
        • Table Figure 50: Number of Products by Top 10 Mechanism of Actions, Dyslipidemia
        • Table Figure 51: Number of Products by Stage and Top 10 Mechanism of Actions, Dyslipidemia
        • Table Number of Products by Stage and Mechanism of Action, Dyslipidemia
      • Assessment by Route of Administration
        • Table Figure 52: Number of Products by Routes of Administration, Dyslipidemia
        • Table Figure 53: Number of Products by Stage and Routes of Administration, Dyslipidemia
        • Table Number of Products by Stage and Route of Administration, Dyslipidemia
      • Assessment by Molecule Type
        • Table Figure 54: Number of Products by Molecule Types, Dyslipidemia
        • Table Figure 55: Number of Products by Stage and Molecule Types, Dyslipidemia
        • Table Number of Products by Stage and Molecule Type, Dyslipidemia
    • Thromboembolism
      • Assessment by Monotherapy Products
        • Table Figure 56: Assessment by Monotherapy Products, Thromboembolism
        • Table Assessment by Monotherapy Products, Thromboembolism
      • Assessment by Target
        • Table Figure 57: Number of Products by Targets, Thromboembolism
        • Table Figure 58: Number of Products by Stage and Targets, Thromboembolism
        • Table Number of Products by Stage and Target, Thromboembolism
      • Assessment by Mechanism of Action
        • Table Figure 59: Number of Products by Mechanism of Actions, Thromboembolism
        • Table Figure 60: Number of Products by Stage and Mechanism of Actions, Thromboembolism
        • Table Number of Products by Stage and Mechanism of Action, Thromboembolism
      • Assessment by Route of Administration
        • Table Figure 61: Number of Products by Routes of Administration, Thromboembolism
        • Table Figure 62: Number of Products by Stage and Routes of Administration, Thromboembolism
        • Table Number of Products by Stage and Route of Administration, Thromboembolism
      • Assessment by Molecule Type
        • Table Figure 63: Number of Products by Molecule Types, Thromboembolism
        • Table Figure 64: Number of Products by Stage and Molecule Types, Thromboembolism
        • Table Number of Products by Stage and Molecule Type, Thromboembolism
    • Heart Failure
      • Acute Heart Failure
        • Table Figure 65: Assessment by Monotherapy Products, Acute Heart Failure
        • Table Assessment by Monotherapy Products, Acute Heart Failure
      • Assessment by Target
        • Table Figure 66: Number of Products by Top 10 Targets, Acute Heart Failure
        • Table Figure 67: Number of Products by Stage and Top 10 Targets, Acute Heart Failure
        • Table Number of Products by Stage and Target, Acute Heart Failure
      • Assessment by Mechanism of Action
        • Table Figure 68: Number of Products by Top 10 Mechanism of Actions, Acute Heart Failure
        • Table Figure 69: Number of Products by Stage and Top 10 Mechanism of Actions, Acute Heart Failure
        • Table Number of Products by Stage and Mechanism of Action, Acute Heart Failure
      • Assessment by Route of Administration
        • Table Figure 70: Number of Products by Routes of Administration, Acute Heart Failure
        • Table Figure 71: Number of Products by Stage and Routes of Administration, Acute Heart Failure
        • Table Number of Products by Stage and Route of Administration, Acute Heart Failure
      • Assessment by Molecule Type
        • Table Figure 72: Number of Products by Molecule Types, Acute Heart Failure
        • Table Figure 73: Number of Products by Stage and Molecule Types, Acute Heart Failure
        • Table Number of Products by Stage and Molecule Type, Acute Heart Failure
      • Congestive Heart Failure (Heart Failure)
        • Table Figure 74: Assessment by Monotherapy Products, Congestive Heart Failure (Heart Failure)
        • Table Assessment by Monotherapy Products, Congestive Heart Failure (Heart Failure)
      • Assessment by Combination Products
        • Table Assessment by Combination Products, Congestive Heart Failure (Heart Failure)
      • Assessment by Target
        • Table Figure 75: Number of Products by Top 10 Targets, Congestive Heart Failure (Heart Failure)
        • Table Figure 76: Number of Products by Stage and Top 10 Targets, Congestive Heart Failure (Heart Failure)
        • Table Number of Products by Stage and Target, Congestive Heart Failure (Heart Failure)
      • Assessment by Mechanism of Action
        • Table Figure 77: Number of Products by Top 10 Mechanism of Actions, Congestive Heart Failure (Heart Failure)
        • Table Figure 78: Number of Products by Stage and Top 10 Mechanism of Actions, Congestive Heart Failure (Heart Failure)
        • Table Number of Products by Stage and Mechanism of Action, Congestive Heart Failure (Heart Failure)
      • Assessment by Route of Administration
        • Table Figure 79: Number of Products by Top 10 Routes of Administration, Congestive Heart Failure (Heart Failure)
        • Table Figure 80: Number of Products by Stage and Top 10 Routes of Administration, Congestive Heart Failure (Heart Failure)
        • Table Number of Products by Stage and Route of Administration, Congestive Heart Failure (Heart Failure)
      • Assessment by Molecule Type
        • Table Figure 81: Number of Products by Top 10 Molecule Types, Congestive Heart Failure (Heart Failure)
        • Table Figure 82: Number of Products by Stage and Top 10 Molecule Types, Congestive Heart Failure (Heart Failure)
        • Table Number of Products by Stage and Molecule Type, Congestive Heart Failure (Heart Failure)
      • Chronic Heart Failure
        • Table Figure 83: Assessment by Monotherapy Products, Chronic Heart Failure
        • Table Assessment by Monotherapy Products, Chronic Heart Failure
      • Assessment by Combination Products
        • Table Assessment by Combination Products, Chronic Heart Failure
      • Assessment by Target
        • Table Figure 84: Number of Products by Top 10 Targets, Chronic Heart Failure
        • Table Figure 85: Number of Products by Stage and Top 10 Targets, Chronic Heart Failure
        • Table Number of Products by Stage and Target, Chronic Heart Failure
      • Assessment by Mechanism of Action
        • Table Figure 86: Number of Products by Top 10 Mechanism of Actions, Chronic Heart Failure
        • Table Figure 87: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Heart Failure
        • Table Number of Products by Stage and Mechanism of Action, Chronic Heart Failure
      • Assessment by Route of Administration
        • Table Figure 88: Number of Products by Routes of Administration, Chronic Heart Failure
        • Table Figure 89: Number of Products by Stage and Routes of Administration, Chronic Heart Failure
        • Table Number of Products by Stage and Route of Administration, Chronic Heart Failure
      • Assessment by Molecule Type
        • Table Figure 90: Number of Products by Molecule Types, Chronic Heart Failure
        • Table Figure 91: Number of Products by Stage and Molecule Types, Chronic Heart Failure
        • Table Number of Products by Stage and Molecule Type, Chronic Heart Failure
  • Dormant Projects
    • Hypertension
      • Table Hypertension - Dormant Projects
    • Dyslipidemia
      • Table Dyslipidemia - Dormant Projects
    • Thromboembolism
      • Table Thromboembolism - Dormant Projects
    • Heart Failure
      • Acute Heart Failure
        • Table Acute Heart Failure - Dormant Projects
      • Congestive Heart Failure (Heart Failure)
        • Table Congestive Heart Failure (Heart Failure) - Dormant Projects
      • Chronic Heart Failure
        • Table Chronic Heart Failure - Dormant Projects
  • Discontinued Products
    • Hypertension
      • Table Hypertension - Discontinued Products
    • Dyslipidemia
      • Table Dyslipidemia - Discontinued Products
    • Thromboembolism
      • Table Thromboembolism - Discontinued Products
    • Heart Failure
      • Acute Heart Failure
        • Table Acute Heart Failure - Discontinued Products
      • Congestive Heart Failure (Heart Failure)
        • Table Congestive Heart Failure (Heart Failure) - Discontinued Products
      • Chronic Heart Failure
        • Table Chronic Heart Failure - Discontinued Products
  • Product Development Milestones
    • Hypertension
      • Featured News & Press Releases
      • Dec 07, 2016: Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension
      • Dec 05, 2016: SteadyMed Provides Update on IPR Hearing
      • Nov 29, 2016: A1M Pharma has successfully conducted preclinical toxicology/safety studies within preeclampsia
      • Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)
      • Nov 17, 2016: Rare lung disease patients fear lengthy negotiation trend will delay access to another new therapy, putting lives at risk
      • Nov 07, 2016: Actelion announces positive results of the MERIT study with macitentan in patients with chronic thromboembolic pulmonary hypertension
      • Nov 03, 2016: Positive Interim Results From Phase 2 Study Of AIR001 In Patients With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction (PH-HFpEF) Published In Journal Of Clinical Investigation
      • Oct 25, 2016: Orphan drug designation for SER100 in Pulmonary Arterial Hypertension granted in U.S.
      • Oct 06, 2016: Reata Enrolls First Patient in Phase 3 CATALYST Trial of Bardoxolone Methyl in CTD-PAH Patients and Reports Positive Interim Data From CTD-PAH Patients in Phase 2 LARIAT Trial
      • Sep 29, 2016: Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension
      • Sep 26, 2016: Exelixis Announces Collaborator Daiichi Sankyos Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist
      • Sep 26, 2016: Mast Therapeutics Provides Update on Clinical Development of it's AIR001 Drug Product
      • Sep 14, 2016: Cumberland Pharmaceuticals Announces New Program To Develop Portaban For Portal Hypertension
      • Sep 12, 2016: Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016
    • Dyslipidemia
      • Featured News & Press Releases
      • Jul 11, 2016: Wests SmartDose Drug Delivery Technology Platform Selected by Amgen for Pushtronex System
      • Jun 28, 2016: Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid
      • Jun 11, 2016: New Scientific Data of Investigational Lipaglyn (Saroglitazar), and Real World Data in Patients will be Featured at American Diabetes Association (ADA) 76th Scientific Sessions
      • May 24, 2016: New study results show cholesterol-lowering medication, Repatha (evolocumab), lowers LDL-C when self-administered in at-home setting
      • May 24, 2016: Two presentations highlighting Zydus drug, Lipaglyn will be featured at the AACE Annual meeting
      • May 23, 2016: BioRestorative Therapies Announces Promising Data to Advance its Program for the Treatment of Metabolic Disorders
      • May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen
      • May 11, 2016: Cigna's New Value-Based Contract with Amgen for Repatha
      • May 04, 2016: Esperion Therapeutics Provides Bempedoic Acid Development Program Updates
      • May 02, 2016: Allergan Receives FDA Approval and Launches First Generic Version of CRESTOR (rosuvastatin)
      • Apr 04, 2016: New study results of Repatha (evolocumab) in statin-intolerant patients published in Journal of the American Medical Association
      • Apr 03, 2016: Positive Efficacy And Tolerability Study Of Repatha (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association"
      • Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab
      • Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab
    • Thromboembolism
      • Featured News & Press Releases
      • May 23, 2016: Portola Pharmaceuticals Announces Upcoming Data Presentation on Betrixaban at International Society on Thrombosis and Haemostasis 2016 Scientific and Standardization Committee Meeting
      • Apr 06, 2016: Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemostasis SSC Meeting 2016 on May 27, 2016
      • Mar 30, 2016: Bristol-Myers Squibb And Pfizer Announce Global Real-World Data Program And Present New Analyses Of Eliquis (Apixaban) At The American College Of Cardiology'S 65Th Annual Scientific Session
      • Mar 24, 2016: Portola Pharmaceuticals Announces Topline Results from Phase 3 APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
      • Dec 07, 2015: First Data Unveiled from CALLISTO Program Examining the Use of XARELTO (rivaroxaban) for Treating Blood Clots in People with Cancer
      • Nov 30, 2015: New Data from Bayer's Portfolio in Thrombosis to be Presented at ASH 2015
      • Nov 06, 2015: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association Scientific Sessions 2015
      • Oct 30, 2015: Portola Pharmaceuticals Completes Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Prevention of Blood Clots in Acute Medically IllPatients
      • Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
      • Oct 13, 2015: Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
      • Sep 24, 2015: Bayer's Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis
      • Sep 24, 2015: Bayer's Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis
      • Jul 12, 2015: NICE recommends edoxaban tosylate (Lixiana) for treating and preventing potentially fatal blood clots
      • Jun 18, 2015: Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer
    • Heart Failure
      • Acute Heart Failure
      • Congestive Heart Failure (Heart Failure)
      • Chronic Heart Failure
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report